U.S. Biosecure Act Sparks Concerns Over Pharmaceutical Decoupling with China
The U.S. Biosecure Act mandates pharmaceutical companies to decouple from key Chinese suppliers by 2032, stirring debates over its impact on the global pharmaceutical industry and U.S.-China relations.